Overview

• Biopharmaceutical company reported Q4 product revenue of $190 mln, driven by SYFOVRE sales

• Net income for 2025 was $22 mln, compared to a net loss in 2024

• Company plans regulatory submission for SYFOVRE prefilled syringe in 2026

Outlook

• Apellis projects full-year 2025 net product revenues of $689 mln

• Company plans SYFOVRE prefilled syringe regulatory submission in first half of 2026

• Apellis expects cash and projected revenues to fund operations to profitability

Result Drivers

• SYFOVRE DEMAND - SYFOVRE saw a 17% increase in injections year-over-year, maintaining market leadership in geographic atrophy

• EMPAVELI LAUNCH SUCCESS - EMPAVELI achieved strong early launch in C3G and IC-MPGN, with favorable payer access and 267 patient start forms

• PIPELINE ADVANCEMENT - Apellis advanced its pipeline with ongoing trials and regulatory plans for SYFOVRE and EMPAVELI

Company press release: ID:nGNX3nzxMd

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 7 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Apellis Pharmaceuticals Inc is $31.50, about 40.2% above its February 23 closing price of $22.47

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)